Limosilactobacillus fermentum from buffalo milk is suitable for potential biotechnological process development and inhibits Helicobacter pylori in a gastric epithelial cell model

D’ambrosio, Sergio; Ventrone, Michela; Fusco, Alessandra; Casillo, Angela; Dabous, Azza; Cammarota, Marcella; Corsaro, Maria Michela; Donnarumma, Giovanna; Schiraldi, Chiara; Cimini, Donatella

doi:10.1016/j.btre.2022.e00732

Cited by 14 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that substantial differences in the results obtained in the 3 different tests are not appreciated, could mean that at the basis of the inhibition of H. pylori mediated by L. brevis , different mechanisms are involved simultaneously, including those previously hypothesized, but it is also interesting to underline how this behavior is species-specific, in fact, as observed in our previous work ( D’Ambrosio et al, 2022 ), using viable cells of L. fermentum the inhibition of H. pylori proved efficient only in the displacement assay.…”

Section: Discussionmentioning

confidence: 81%

Optimization of growth of Levilactobacillus brevis SP 48 and in vitro evaluation of the effect of viable cells and high molecular weight potential postbiotics on Helicobacter pylori

Cimini

D’ambrosio²,

Stellavato³

et al. 2022

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

Several Levilactobacillus brevis strains have the potential to be used as probiotics since they provide health benefits due to the interaction of live cells, and of their secreted products, with the host (tissues). Therefore, the development of simple fermentation processes that improve cell viability to reduce industrial production costs, and at the same time the characterization and biological evaluation of cell-free postbiotics that can further promote application, are of great interest. In the present study, small scale batch fermentations on semi defined media, deprived of animal derived raw materials, were used to optimize growth of L. brevis SP48, reaching 1.2 ± 0.4 × 1010 CFU/ml of viable cells after 16 h of growth. Displacement, competition, and inhibition assays compared the effect, on Helicobacter pylori, of L. brevis cells to that of its partially purified potentially postbiotic fraction rich in exopolysaccharides and proteins. The expression of pro and anti-inflammatory biochemical markers indicated that both samples activated antimicrobial defenses and innate immunity in a gastric model. Moreover, these compounds also acted as modulators of the inflammatory response in a gut in vitro model. These data demonstrate that the high molecular weight compounds secreted by L. brevis SP48 can contrast H. pylori and reduce inflammation related to intestinal bowel disease, potentially overcoming issues related to the preservation of probiotic viability.

show abstract

Section: Discussionmentioning

confidence: 81%

Optimization of growth of Levilactobacillus brevis SP 48 and in vitro evaluation of the effect of viable cells and high molecular weight potential postbiotics on Helicobacter pylori

Cimini

D’ambrosio²,

Stellavato³

et al. 2022

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, the activity of L. fermentum was evaluated in a gastric epithelial cell model demonstrating the modulation of inflammatory cytokines and the inhibition of H. pylori [ 32 ]; moreover, other L. fermentum strains showed anti-infectious and immunomodulatory properties [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

“…Lactobacillus strains, including Limosilactobacillus fermentum isolated from buffalo milk [ 32 ], Levilactobacillus brevis SP-48, Lacticaseibacillus rhamnosus IMC501, Limosilactobacillus reuteri LR92 and Lacticaseibacillus paracasei IMC502 provided by the Incube project leader, R&D—IBSA Farmaceutici Italia, were cultivated in bioreactor fermentation processes and freeze-dried to obtain the powders used as the starting material. Before the experiment, the powders were resuspended and grown in Man, Rogosa, and Sharpe broth (MRS-Oxoid) at 37 °C in microaerophilic conditions for 24 h.…”

Section: Methodsmentioning

confidence: 99%

“…The enhancement of epithelial barrier function and the ability to regulate both innate and adaptive immunity are some of the proposed mechanisms by which certain lactobacilli may confer beneficial activities [ 29 ]; these activities may depend on the Lactobacillus strain and species as well as the target population and the intestinal mucosa resilience capacity, and can play a role in disease prevention and treatment in the host through immune stimulation and regulation. Extensive studies have shown that lactobacilli have the capacity to modulate the expression of pro- and anti-inflammatory cytokines [ 30 , 31 , 32 ] and the innate immune response [ 33 ]. Among the innate immune response mechanisms, of particular interest is the production of the antimicrobial peptides (AMPs), including human beta-defensin 2 (HBD-2), an inducible AMP, identified in psoriatic lesions as the most abundant AMP, produced by numerous epithelia and with a broad spectrum of action against Gram-positive and Gram-negative bacteria, fungi and the envelopes of some viruses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Evaluation of the Most Active Probiotic Strains Able to Improve the Intestinal Barrier Functions and to Prevent Inflammatory Diseases of the Gastrointestinal System

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: The integrity of the intestinal barrier is fundamental to gut health and homeostasis; its damage can increase intestinal permeability, with translocation of bacteria and/or endotoxins from gut, and the onset of various intestinal diseases. Lactobacillus spp. is one of the most common probiotics normally found in fermented foods and dairy products and is known for its anti-inflammatory and immunomodulatory properties and for its ability to protect and enhance the intestinal barrier functions. The aim of this work was to evaluate the ability of different strains of Lactobacillus spp. to improve in vitro the integrity of the intestinal barrier, to exert anti-inflammatory and immunomodulatory activity and to prevent Salmonella Typhimurium and enteroinvasive Escherichia coli (EIEC) infections. Methods: We analyzed the cellular expression of tight junctions, antimicrobial peptide HBD-2, pro-inflammatory cytokines and the inhibition of pathogens adhesion and invasion in a model of co-cultured epithelial cells treated with Lactobacillus spp. Results: L. brevis, L. reuteri and L. rhamnosus proved to be more effective in protecting the intestinal epithelium. Conclusions: These in vitro studies can help select strains particularly active in their intended use to obtain consortia formulations that can have as much maximum yield as possible in terms of patient benefit.

show abstract

“…In accord with this new taxonomic order, Lactobacillus fermentum has been renamed Limosilactobacillus fermentum and qualified as gram-positive, coccoid, or rod-shaped, aerotolerant or anaerobic, and heterofermentative. L. fermentum has been generally isolated from fermented plant materials including cereals, dairy products, feces, manure, sewage, oral cavity, human vagina, and breast milk (Zheng et al, 2020; D’ambrosio et al, 2022). Moreover, it has been reported that L fermentum shows health-promoting effects on the host when administered time-dependently.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of metabolic and functional properties of cholesterol-reducing and GABA-producerLimosilactobacillus fermentumstrain AGA52 isolated from lactic acid fermented Shalgam by usingin vitroandin silicoprobiogenomic approaches

Yetiman

Horzum²,

Akbulut

2022

Preprint

View full text Add to dashboard Cite

This study aimed to characterize the genomic and metabolic properties of a novel Lb. fermentum strain AGA52 which was isolated from a lactic acid fermented beverage called Shalgam. The genome size of AGA52 was 2,001,084 bp, which is predicted to carry 2,024 genes, including 50 tRNAs, 3 rRNAs, 3ncRNAs, 15 CRISPR repeats, 14 CRISPR spacers, and 1 CRISPR array. The genome has a GC content of 51.82% including 95 predicted pseudogenes, 56 complete or partial transposases and 2 intact prophages. The similarity of the clusters of orthologous groups (COG) was analysed by comparison with the other Lb. fermentum strains. The detected resistome on the genome of AGA52 was found to be intrinsic originated. Based on genome analyses many CAZYmes were identified that are responsible for carbohydrate degradation and adaptation to gastrointestinal conditions. Besides, it has been determined that AGA52 has an obligate heterofermentative carbohydrate metabolism due to the absence of the 1-phosphofructokinase (pfK) enzyme. Additionally, it is determined that the strain has a higher antioxidant capacity and is adaptable to gastrointestinal simulated environments. It was also observed that the AGA52 has antimicrobial activity against Y. Enterocolitica ATCC9610, B. cereus ATCC33019, S. enterica sv. Typhimurium, E.coli O157:h7 ATCC43897, L.monocytogenes ATCC7644, K.pneumoniae ATCC13883, and P. vulgaris ATCC8427. Cholesterol assimilation (33.9%) and GABA production capacities were also confirmed by in silico and in vitro. Overall, investigation of genomic and metabolic features of the AGA52 revealed that is a potential psychobiotic and probiotic dietary supplement candidate and can bring functional benefits to the host.

show abstract

Limosilactobacillus fermentum from buffalo milk is suitable for potential biotechnological process development and inhibits Helicobacter pylori in a gastric epithelial cell model

Cited by 14 publications

References 59 publications

Optimization of growth of Levilactobacillus brevis SP 48 and in vitro evaluation of the effect of viable cells and high molecular weight potential postbiotics on Helicobacter pylori

Optimization of growth of Levilactobacillus brevis SP 48 and in vitro evaluation of the effect of viable cells and high molecular weight potential postbiotics on Helicobacter pylori

In Vitro Evaluation of the Most Active Probiotic Strains Able to Improve the Intestinal Barrier Functions and to Prevent Inflammatory Diseases of the Gastrointestinal System

Evaluation of metabolic and functional properties of cholesterol-reducing and GABA-producerLimosilactobacillus fermentumstrain AGA52 isolated from lactic acid fermented Shalgam by usingin vitroandin silicoprobiogenomic approaches

Contact Info

Product

Resources

About